Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Co-Delivery of Eugenol and Dacarbazine by Hyaluronic Acid-Coated Liposomes for Targeted Inhibition of Survivin in Treatment of Resistant Metastatic Melanoma

H. Mishra, PK. Mishra, Z. Iqbal, M. Jaggi, A. Madaan, K. Bhuyan, N. Gupta, N. Gupta, K. Vats, R. Verma, S. Talegaonkar,

. 2019 ; 11 (4) : . [pub] 20190403

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19029143

Grant support
45/67/2018-Nan/BMS Indian Council of Medical Research

While melanoma remains a challenge for oncologists, possibilities are being continuously explored to fight resistant metastatic melanoma more effectively. Eugenol is reported to inhibit survivin protein in breast cancer cells. Survivin is also overexpressed by melanoma cells, and is known to impart resistance to them against chemotherapy-induced apoptosis. To be able to fight resistant melanoma, we formulated hyaluronic acid (HA)-coated liposomes loaded with an effective combination of anti-melanoma agents (Dacarbazine and Eugenol), using a solvent injection method. Quality-by-Design (QbD) was applied to optimize and obtain a final formulation with the desired quality attributes, and within an acceptable size range. The optimized formulation was then subjected to performance analysis in cell lines. Coated-Dacarbazine Eugenol Liposomes were found to possess 95.08% cytotoxicity at a dacarbazine concentration of 0.5 µg/mL, while Dacarbazine Solution showed only 10.20% cytotoxicity at the same concentration. The number of late apoptotic cells was also found to be much higher (45.16% vs. 8.43%). Furthermore, migration assay and proliferation study also revealed significantly higher inhibition of cell migration and proliferation by Coated-Dacarbazine Eugenol Liposomes, signifying its potential against metastasis. Thus, surface-functionalized dacarbazine- and eugenol-loaded liposomes hold great promise against resistant and aggressive metastatic melanoma, with much less unwanted cytotoxicity and reduced doses of the chemotherapeutic agent.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19029143
003      
CZ-PrNML
005      
20190822091654.0
007      
ta
008      
190813s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics11040163 $2 doi
035    __
$a (PubMed)30987266
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mishra, Harshita $u Departmant of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. harshitasharma1088@gmail.com.
245    10
$a Co-Delivery of Eugenol and Dacarbazine by Hyaluronic Acid-Coated Liposomes for Targeted Inhibition of Survivin in Treatment of Resistant Metastatic Melanoma / $c H. Mishra, PK. Mishra, Z. Iqbal, M. Jaggi, A. Madaan, K. Bhuyan, N. Gupta, N. Gupta, K. Vats, R. Verma, S. Talegaonkar,
520    9_
$a While melanoma remains a challenge for oncologists, possibilities are being continuously explored to fight resistant metastatic melanoma more effectively. Eugenol is reported to inhibit survivin protein in breast cancer cells. Survivin is also overexpressed by melanoma cells, and is known to impart resistance to them against chemotherapy-induced apoptosis. To be able to fight resistant melanoma, we formulated hyaluronic acid (HA)-coated liposomes loaded with an effective combination of anti-melanoma agents (Dacarbazine and Eugenol), using a solvent injection method. Quality-by-Design (QbD) was applied to optimize and obtain a final formulation with the desired quality attributes, and within an acceptable size range. The optimized formulation was then subjected to performance analysis in cell lines. Coated-Dacarbazine Eugenol Liposomes were found to possess 95.08% cytotoxicity at a dacarbazine concentration of 0.5 µg/mL, while Dacarbazine Solution showed only 10.20% cytotoxicity at the same concentration. The number of late apoptotic cells was also found to be much higher (45.16% vs. 8.43%). Furthermore, migration assay and proliferation study also revealed significantly higher inhibition of cell migration and proliferation by Coated-Dacarbazine Eugenol Liposomes, signifying its potential against metastasis. Thus, surface-functionalized dacarbazine- and eugenol-loaded liposomes hold great promise against resistant and aggressive metastatic melanoma, with much less unwanted cytotoxicity and reduced doses of the chemotherapeutic agent.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mishra, Pawan Kumar $u Department of Wood Processing, Mendel University in Brno, 61300 Brno, Czech Republic. pawan.mishra@mendelu.cz.
700    1_
$a Iqbal, Zeenat $u Departmant of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. zeenatiqbal@jamiahamdard.ac.in.
700    1_
$a Jaggi, Manu $u Dabur Research Foundation, Ghaziabad 201010, India. manu.jaggi@daburresearch.in.
700    1_
$a Madaan, Alka $u Dabur Research Foundation, Ghaziabad 201010, India. alka.madaan@daburresearch.in.
700    1_
$a Bhuyan, Kimi $u Dabur Research Foundation, Ghaziabad 201010, India. kimi.bhuyan@daburresearch.in.
700    1_
$a Gupta, Namita $u Dabur Research Foundation, Ghaziabad 201010, India. neha.gupta@daburresearch.in.
700    1_
$a Gupta, Neha $u Dabur Research Foundation, Ghaziabad 201010, India. neha.gupta@daburresearch.in.
700    1_
$a Vats, Karnika $u Dabur Research Foundation, Ghaziabad 201010, India. karnika@daburresearch.in.
700    1_
$a Verma, Ritu $u Dabur Research Foundation, Ghaziabad 201010, India. ritu.verma@daburresearch.in.
700    1_
$a Talegaonkar, Sushama $u Departmant of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. stalegaonkar@jamiahamdard.ac.in. Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Govt. of NCT of Delhi, Pushp Vihar, New Delhi 110017, India. stalegaonkar@jamiahamdard.ac.in.
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 11, č. 4 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30987266 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190822091932 $b ABA008
999    __
$a ind $b bmc $g 1434292 $s 1067603
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 11 $c 4 $e 20190403 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a 45/67/2018-Nan/BMS $p Indian Council of Medical Research
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Archiving options